1. Home
  2. CURB vs NVAX Comparison

CURB vs NVAX Comparison

Compare CURB & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CURB
  • NVAX
  • Stock Information
  • Founded
  • CURB 2024
  • NVAX 1987
  • Country
  • CURB United States
  • NVAX United States
  • Employees
  • CURB N/A
  • NVAX N/A
  • Industry
  • CURB
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CURB
  • NVAX Health Care
  • Exchange
  • CURB NYSE
  • NVAX Nasdaq
  • Market Cap
  • CURB 2.5B
  • NVAX 2.0B
  • IPO Year
  • CURB N/A
  • NVAX 1995
  • Fundamental
  • Price
  • CURB $23.18
  • NVAX $9.00
  • Analyst Decision
  • CURB Buy
  • NVAX Buy
  • Analyst Count
  • CURB 5
  • NVAX 6
  • Target Price
  • CURB $25.69
  • NVAX $17.83
  • AVG Volume (30 Days)
  • CURB 461.8K
  • NVAX 3.6M
  • Earning Date
  • CURB 02-07-2025
  • NVAX 11-12-2024
  • Dividend Yield
  • CURB N/A
  • NVAX N/A
  • EPS Growth
  • CURB N/A
  • NVAX N/A
  • EPS
  • CURB 0.06
  • NVAX N/A
  • Revenue
  • CURB $111,428,000.00
  • NVAX $885,193,000.00
  • Revenue This Year
  • CURB N/A
  • NVAX N/A
  • Revenue Next Year
  • CURB N/A
  • NVAX N/A
  • P/E Ratio
  • CURB $381.51
  • NVAX N/A
  • Revenue Growth
  • CURB 52.36
  • NVAX N/A
  • 52 Week Low
  • CURB $18.80
  • NVAX $3.53
  • 52 Week High
  • CURB $25.35
  • NVAX $23.86
  • Technical
  • Relative Strength Index (RSI)
  • CURB N/A
  • NVAX 50.66
  • Support Level
  • CURB N/A
  • NVAX $8.13
  • Resistance Level
  • CURB N/A
  • NVAX $9.75
  • Average True Range (ATR)
  • CURB 0.00
  • NVAX 0.47
  • MACD
  • CURB 0.00
  • NVAX 0.14
  • Stochastic Oscillator
  • CURB 0.00
  • NVAX 53.70

About CURB CURBLINE PPTYS CORP

Curbline Properties Corp is a publicly-traded REIT operating Convenience retail properties, offering enhanced access and visibility relative to other retail property types. The properties generally consist of a ubiquitous row of shop units along with dedicated parking leased to a diversified mixture of national and local service and restaurant tenants that cater to daily convenience trips from the growing suburban population.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Share on Social Networks: